New Orleans, LA - ASH 2022 - Your Profile Photo courtesy of Janssen: Rajesh Narwal rajesh.narwal@bms.com at the 64th American Society of Hematology’s Annual Meeting, Saturday, December 10, 2022, at the Ernest Morial Convention Center Photo by © ASH/Todd Buchanan 2022

Rajesh Narwal is a visionary biopharmaceutical executive with nearly two decades of leadership experience driving innovation across the drug development continuum — from early discovery through regulatory approval. With experience from top tier organizations, including FDA, MedImmune, AstraZeneca, and Bristol Myers Squibb and a deep portfolio of work spanning Oncology/Hematology, Immunology, Neuroscience, and Infectious Diseases, Rajesh Narwal has successfully led high-impact global programs and cross-functional teams that have advanced breakthrough therapies to patients worldwide.
Throughout his career, Rajesh Narwal has played a pivotal role in the development of both biologics and small molecule modalities, including monoclonal and multi-specific antibodies, T-cell/NK cell engagers, ADCs, and novel protein degraders such as CELMoD and LDD platforms. He provided valuable strategic and cross-functional leadership to key landmark therapies including Imfinzi, Imjudo, Enhertu, Blincyto, and Nirsevimab. His global program leadership includes multiple oncology/hematology assets such as BCL6-LDD, HbF-CELMOD, SIRPα-mAb, and BCMA-ADC.
Known for combining scientific rigor with business acumen, Rajesh Narwal brings deep expertise across clinical development, clinical pharmacology, pharmacometrics, translational science, biostatistics, advanced analytics and regulatory strategy. His track record of delivering results in matrixed, fast-paced environments is matched by a passion for translating innovation into real-world impact for patients.